Antithrombotic properties of pravastatin reducing intra-thrombus fibrin deposition under high shear blood flow conditions

 

 Buy Article Permissions and Reprints

Summary

In addition to lowering cholesterol, the 3-hydroxyl-3-methylglutaryl coenzyme A reductase inhibitors (statins) have a range of pleiotropic effects that help reduce the risk of adverse cardiovascular events. We sought to understand the molecular mechanisms by which statins could exert anti-platelet actions under physiologic whole blood flow conditions. Using an in vitroperfusion chamber system, we examined the anti-platelet effects of pravastatin under whole blood flow conditions with high or low shear rates. We determined that pravastatin significantly suppressed platelet activation-dependent procoagulant activity, decreasing P-selectin membrane expression, tissue factor accumulation, and thrombin binding within platelet thrombi generated on a von Willebrand factor-surface under high shear rate conditions. These effects resulted in reductions of intra-thrombus fibrin deposition. These antithrombotic properties of pravastatin, which were comparable to those of atorvastatin, could be abrogated by mevalonate. Our experimental approach revealed a novel mechanism mediating the anti-platelet action of statins. Shear rate-dependent antithrombotic activity may explain the favourable effect of pravastatin on the reduction in cardiovascular events that typically occur in vivounder whole blood flow conditions with high shear rates.

• References

• 1 Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation 2000; 101: 207-213.
  CrossrefPubMedGoogle Scholar
• 2 Baigent C, Keech A, Kearney PM. et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-1278.
  CrossrefPubMedGoogle Scholar
• 3 Wolfrum S, Jensen KS, Liao JK. Endothelium-dependent effects of statins. Arterioscler Thromb Vasc Biol 2003; 23: 729-736.
  CrossrefPubMedGoogle Scholar
• 4 Diamant M, Tushuizen ME, Abid-Hussein MN. et al. Simvastatin-induced endothelial cell detachment and microparticle release are prenylation dependent. Thromb Haemost 2008; 100: 489-497.
  Article in Thieme ConnectPubMedGoogle Scholar
• 5 Kleemann R, Verschuren L, de Rooij B-J. et al. Evidence for anti-inflammatory activity of statins and PPAR? activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes in vitro. Blood 2004; 103: 4188-4194.
  CrossrefPubMedGoogle Scholar
• 6 Kruithof EK. Regulation of plasminogen activator inhibitor type 1 gene expression by inflammatory mediators and statins. Thromb Haemost 2008; 100: 969-975.
  Article in Thieme ConnectPubMedGoogle Scholar
• 7 Waters D, Higginson L, Gladstone P. et al. Effects of monotherapy with an HMGCoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography: the Canadian Coronary Atherosclerosis Intervention Trial. Circulation 1994; 89: 959-968.
  CrossrefPubMedGoogle Scholar
• 8 Sanguigni V, Pignatelli P, Lenti L. et al. Short-term treatment with atorvastatin reduces platelet CD40 ligand and thrombin generation in hypercholesterolemic patients. Circulation 2005; 111: 412-419.
  CrossrefPubMedGoogle Scholar
• 9 Redecha P, van Rooilen N, Torry D. et al. Pravastatin prevents miscarriages in mice: role of tissue factor in placental and fatal injury. Blood 2009; 113: 4101-4109.
  CrossrefPubMedGoogle Scholar
• 10 Aberg M, Johnell M, Wickström M. et al. Simvastatin reduces the production of prothrombotic prostasomes in human prostate cancer cells. Thromb Haemost 2008; 100: 655-662.
  Article in Thieme ConnectPubMedGoogle Scholar
• 11 Ramacciotti E, Hawley AE, Farris DM. et al. Leukocyte- and platelet-derived microparticles correlate with thrombus weight and tissue factor activity in an experimental mouse model of venous thrombosis. Thromb Haemost 2009; 101: 748-754.
  Article in Thieme ConnectPubMedGoogle Scholar
• 12 Sugimoto M, Mohri H, McClintock RA. et al. Identification of discontinuous von Willebrand factor sequences involved in complex formation with botrocetin. A model for the regulation of von Willebrand factor binding to platelet glycoprotein Ib. J Biol Chem 1991; 266: 18172-18178.
  PubMedGoogle Scholar
• 13 Kansas G. Selectins and their ligands: Current concepts and controversies. Blood 1996; 88: 3259-3287.
  PubMedGoogle Scholar
• 14 Crawley J, Lupu F, Westmuckett AD. et al. Expression, localization, and activity of tissue factor pathway inhibitor in normal and atherosclerotic human vessels. Arterioscler Thromb Vasc Biol 2000; 20: 1362-1373.
  CrossrefPubMedGoogle Scholar
• 15 Abcam Inc. product data sheet: Protocol for mouse monoclonal [109–04] to thrombin (ab17199). Available at http://www.abcam.com/Thrombin-antibody-5G9-ab17199.html
  PubMedGoogle Scholar
• 16 Kudryk B, Rohoza A, Ahadi M. et al. Specificity of a monoclonal antibody for the NH2-terminal region of fibrin. Molec Immun 1984; 21: 89-94.
  CrossrefPubMedGoogle Scholar
• 17 Mizuno T, Sugimoto M, Matsui H. et al. Visual evaluation of blood coagulation during mural thrombogenesis under high shear flow. Thromb Res 2008; 121: 855-864.
  CrossrefPubMedGoogle Scholar
• 18 Matsui H, Sugimoto M, Mizuno T. et al. Distinct and concerted functions of von Willebrand factor and fibrinogen in mural thrombus growth under high shear flow. Blood 2002; 100: 3604-3610.
  CrossrefPubMedGoogle Scholar
• 19 Sugimoto M, Matsui H, Mizuno T. et al. Mural thrombus generation in type 2A and 2B von Willebrand disease under flow conditions. Blood 2003; 101: 915-920.
  CrossrefPubMedGoogle Scholar
• 20 Shida Y, Nishio K, Sugimoto M. et al. Functional imaging of shear-dependent activity of ADAMTS13 in regulating mural thrombus growth under whole blood flow conditions. Blood 2008; 111: 1295-1298.
  PubMedGoogle Scholar
• 21 Giessen PLA, Rauch U, Bohmann B. et al. Blood-borne tissue factor: another view of thrombosis. Proc Natl Acad Sci USA 1999; 96: 2311-2315.
  CrossrefPubMedGoogle Scholar
• 22 Balasubramanian V, Vele O, Nemerson Y. Local shear conditions and platelet aggregates regulate the incorporation and activity of circulating tissue factor in exvivo thrombi. Thromb Haemost 2002; 88: 822-826.
  Article in Thieme ConnectPubMedGoogle Scholar
• 23 Falati S, Liu Q, Gross P. et al. Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin. J Exp Med 2003; 197: 1585-1598.
  CrossrefPubMedGoogle Scholar
• 24 Undas A, Brummel KE, Musial J. et al. Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V, and factor XIII and by enhancing factor Va inactivation. Circulation 2001; 103: 2248-2253.
  CrossrefPubMedGoogle Scholar
• 25 Dajani EZ, Shahwan TG, Dajani NE. Statins, platelet aggregation and coronary heart disease. J Assoc Acad Minor Phys 2002; 13: 27-31.
  PubMedGoogle Scholar
• 26 Cortellaro M, Cofrancesco E, Arbustini E. et al. Atorvastatin and thrombogenicity of the carotid atherosclerotic plaque: the ATROCAP study. Thromb Haemost 2002; 88: 41-47.
  Article in Thieme ConnectPubMedGoogle Scholar
• 27 Santos MT, Fuset MP, Ruano M. et al. Effect of atorvastatin on platelet thromboxane A(2) synthesis in aspirin-treated patients with acute myocardial infarction. Am J Cardiol 2009; 104: 1618-1623.
  CrossrefPubMedGoogle Scholar
• 28 Savage B, Almus-Jacobs F, Ruggeri ZM. Specific synergy of multiple substrate-receptor interactions in platelet thrombus formation under flow. Cell 1998; 94: 657-666.
  CrossrefPubMedGoogle Scholar
• 29 Tsuji S, Sugimoto M, Miyata S. et al. Real-time analysis of mural thrombus formation in various platelet aggregation disorders: distinct shear-dependent roles of platelet receptors and adhesive proteins under flow. Blood 1999; 94: 968-975.
  PubMedGoogle Scholar
• 30 Savage B, Saldivar E, Ruggeri ZM. Initiation of platelet adhesion by attachment onto fibrinogen or translocation on von Willebrand factor. Cell 1996; 84: 289-297.
  CrossrefPubMedGoogle Scholar
• 31 Kuwahara M, Sugimoto M, Tsuji S. et al. Cytosolic calcium changes in a process of platelet adhesion and cohesion on a von Willebrand factor-coated surface under flow conditions. Blood 1999; 94: 1149-1155.
  PubMedGoogle Scholar
• 32 Kuwahara M, Sugimoto M, Tsuji S. et al. Platelet shape changes and adhesion under high shear flow. Arterioscler Thromb Vasc Biol 2002; 22: 329-334.
  CrossrefPubMedGoogle Scholar
• 33 Fuster V, Badimon L, Badimon JJ. et al. The pathogenesis of coronary artery disease and the acute coronary syndromes (part I). N Engl J Med 1992; 326: 242-250.
  CrossrefPubMedGoogle Scholar
• 34 Pan HY, DeVault AR, Wang-Iverson D. et al. Comparative pharmacokinetics and pharmacodynamics of pravastatin and lovastatin. J Clin Pharmacol 1990; 30: 1128-1135.
  CrossrefPubMedGoogle Scholar
• 35 Ohkawara H, Ishibashi T, Sakamoto T. et al. Thrombin-induced rapid geranylgeranylation of RhoA as an essential process for RhoA activation in endothelial cells. J Biol Chem 2005; 280: 10182-10188.
  CrossrefPubMedGoogle Scholar